Tandem Diabetes (TNDM) Misses Q2 EPS by 5c; Guides FY Revenue Below Views
(Updated - August 3, 2023 5:46 PM EDT)
Tandem Diabetes (NASDAQ: TNDM) reported Q2 EPS of ($0.55), $0.05 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $198.2 million versus the consensus estimate of $197.62 million.
GUIDANCE:
Tandem Diabetes sees FY2023 revenue of $785 million, versus the consensus of $881.47 million.
For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.